Compare BNGO & LNAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BNGO | LNAI |
|---|---|---|
| Founded | 2003 | N/A |
| Country | United States | United States |
| Employees | N/A | 29 |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.8M | 11.7M |
| IPO Year | 2018 | N/A |
| Metric | BNGO | LNAI |
|---|---|---|
| Price | $1.26 | $2.95 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $7.00 | N/A |
| AVG Volume (30 Days) | 163.2K | ★ 3.0M |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 94.50 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $12,000,735.00 | N/A |
| Revenue This Year | $14.99 | N/A |
| Revenue Next Year | $34.73 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 26.26 | N/A |
| 52 Week Low | $1.06 | $0.15 |
| 52 Week High | $5.50 | $3.38 |
| Indicator | BNGO | LNAI |
|---|---|---|
| Relative Strength Index (RSI) | 54.72 | 87.23 |
| Support Level | $1.10 | $0.89 |
| Resistance Level | $1.31 | N/A |
| Average True Range (ATR) | 0.06 | 0.21 |
| MACD | 0.00 | 0.28 |
| Stochastic Oscillator | 61.57 | 87.35 |
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in the Americas, EMEA, and Asia Pacific, of which the EMEA region generates the majority of its revenue. It generates product revenue from sales of its OGM and Ionic Purification systems and consumables, which include its instruments and their VIA software.
Lunai Bioworks Inc is a biopharmaceutical company. Through its subsidiaries, it is mainly focused on developing allogeneic cell and gene therapies to promote stronger immune system responses, potentially for long-term or life-long cancer remission in some of the deadliest cancers. The group is engaged in the development of RENB-DC11 and RENB-DC20 (potential cell therapeutic vaccine candidates for different types of cancer); a proprietary AI platform that analyzes genetics to provide earlier and more accurate cancer diagnosis; and machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. The group's reportable segments are: RENB, BioSymetrics, and RENC. Geographically, it operates in the United States and Netherlands.